Six weeks after revealing that an interim analysis of a phase 3 trial showed that AstraZeneca’s blood cancer drug Calquence plus chemoimmunotherapy worked in previously untreated mantle cell lymphoma (MCL) patients, the company has put numbers to its claim.
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9 years1. Additional findings from pooled analysis of three Phase 3 studies show treatment with ibrutinib has the potential to achieve comparable overall survival to the general European population2
Johnson & Johnson Announces Expansion of IMBRUVICA (ibrutinib) Label in the U.S.
An Imbruvica combo regimen could have a new future in MCL
Additional data from the Phase 2 CAPTIVATE study, show 82 percent of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did...
AbbVie recently filed a patent infringement lawsuit against BeiGene over their blockbuster BTK franchises. Although the litigation was launched right after a patent’s issuance, AbbVie may actually have a case here, according to one expert.
The addition of ibrutinib (Imbruvica) to bendamustine plus rituximab (Rituxan; BR) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) did not lead to a statistically significant improvement in progression-free survival (PFS) vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma (MZL), according to findings from the phase 3 SELENE trial (NCT01974440) presented at the 17th Annual International Conference on Malignant Lymphoma.1
The combination of ibrutinib (Imbruvica), obinutuzumab (Gazyva), and venetoclax (Venclexta) was associated with prolonged survival in patients with newly diagnosed or relapsed/refractory mantle cell lymphoma (MCL), according to long-term follow-up data from the phase 1/2 OAsIs trial (NCT02558816) presented at the 2023 EHA Congress.1
Dazzling trial data, followed by FDA approval three months ago in the most common form of leukemia have set BeiGene’s Brukinsa up to become the dominant force in treating blood cancer.
High Wycombe, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended Imbruvica® (ibrutinib) plus venetoclax as an option for untreated chronic lymphocytic leukaemia (CLL) in adults.[1]